Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Total Liabilities (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Total Liabilities for 7 consecutive years, with $33.0 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Total Liabilities rose 17.85% year-over-year to $33.0 million, compared with a TTM value of $33.0 million through Sep 2019, up 17.85%, and an annual FY2018 reading of $28.5 million, up 4.39% over the prior year.
  • Total Liabilities was $33.0 million for Q3 2019 at Larimar Therapeutics, up from $31.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $33.0 million in Q3 2019 and bottomed at $7.0 million in Q3 2017.
  • Average Total Liabilities over 5 years is $19.8 million, with a median of $17.7 million recorded in 2015.
  • The sharpest move saw Total Liabilities plummeted 50.52% in 2016, then soared 298.18% in 2018.
  • Year by year, Total Liabilities stood at $20.0 million in 2015, then tumbled by 50.52% to $9.9 million in 2016, then soared by 175.85% to $27.3 million in 2017, then grew by 4.39% to $28.5 million in 2018, then grew by 15.85% to $33.0 million in 2019.
  • Business Quant data shows Total Liabilities for LRMR at $33.0 million in Q3 2019, $31.7 million in Q2 2019, and $27.8 million in Q1 2019.